CZ20032672A3 - CD25 vazebná molekula pro použití při prevenci nebo léčení některých nemocí u pacientů rezistentních na léčbu steroidy - Google Patents

CD25 vazebná molekula pro použití při prevenci nebo léčení některých nemocí u pacientů rezistentních na léčbu steroidy Download PDF

Info

Publication number
CZ20032672A3
CZ20032672A3 CZ20032672A CZ20032672A CZ20032672A3 CZ 20032672 A3 CZ20032672 A3 CZ 20032672A3 CZ 20032672 A CZ20032672 A CZ 20032672A CZ 20032672 A CZ20032672 A CZ 20032672A CZ 20032672 A3 CZ20032672 A3 CZ 20032672A3
Authority
CZ
Czechia
Prior art keywords
steroid
patients
tyr
treatment
binding molecule
Prior art date
Application number
CZ20032672A
Other languages
Czech (cs)
English (en)
Inventor
Stephen David Hearing
Colin Mark Dayan
Michael Roden Norman
Original Assignee
University Of Bristol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27256143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CZ20032672(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0108817A external-priority patent/GB0108817D0/en
Priority claimed from GB0108821A external-priority patent/GB0108821D0/en
Priority claimed from GB0108816A external-priority patent/GB0108816D0/en
Application filed by University Of Bristol filed Critical University Of Bristol
Publication of CZ20032672A3 publication Critical patent/CZ20032672A3/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
CZ20032672A 2001-04-06 2002-04-05 CD25 vazebná molekula pro použití při prevenci nebo léčení některých nemocí u pacientů rezistentních na léčbu steroidy CZ20032672A3 (cs)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0108817A GB0108817D0 (en) 2001-04-06 2001-04-06 Therapy
GB0108821A GB0108821D0 (en) 2001-04-06 2001-04-06 Therapy
GB0108816A GB0108816D0 (en) 2001-04-06 2001-04-06 Therapy

Publications (1)

Publication Number Publication Date
CZ20032672A3 true CZ20032672A3 (cs) 2003-12-17

Family

ID=27256143

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20032672A CZ20032672A3 (cs) 2001-04-06 2002-04-05 CD25 vazebná molekula pro použití při prevenci nebo léčení některých nemocí u pacientů rezistentních na léčbu steroidy

Country Status (21)

Country Link
US (2) US20040146508A1 (https=)
EP (2) EP2058332A1 (https=)
JP (2) JP2005502593A (https=)
KR (2) KR100975042B1 (https=)
CN (1) CN1296386C (https=)
AT (1) ATE408629T1 (https=)
AU (1) AU2002315271B2 (https=)
BR (1) BR0208656A (https=)
CA (1) CA2443405A1 (https=)
CZ (1) CZ20032672A3 (https=)
DE (1) DE60228945D1 (https=)
ES (1) ES2314067T3 (https=)
HU (1) HUP0400986A3 (https=)
IL (2) IL158060A0 (https=)
MX (1) MXPA03009115A (https=)
NO (1) NO20034453L (https=)
NZ (1) NZ528411A (https=)
PL (1) PL363029A1 (https=)
PT (1) PT1379557E (https=)
SK (1) SK12212003A3 (https=)
WO (1) WO2002081508A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2490804C (en) * 2002-06-28 2016-12-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating autoimmune diseases with interferon-beta and il-2r antagonist
WO2005030252A1 (en) * 2003-09-23 2005-04-07 Pdl Biopharma, Inc. Treatment of respiratory diseases with anti-il-2 receptor antibodies
GB0507696D0 (en) * 2005-04-15 2005-05-25 Novartis Ag Organic compounds
CA2617583A1 (en) * 2005-08-02 2007-02-08 Centenary Institute Of Cancer Medicine And Cell Biology Method for identifying regulatory t cells
WO2009145831A1 (en) * 2008-04-02 2009-12-03 Geisinger Clinic Treatment of the idiopathic nephrotic syndrome spectrum diseases using basiliximab
TW201834698A (zh) * 2017-03-03 2018-10-01 國立研究開發法人國立癌症研究中心 抗ｉｌ－７ｒ抗體之抗體藥物共軛物與處置癌或發炎用之包含抗ｉｌ－７ｒ抗體與細胞傷害劑之抗體藥物共軛物之醫藥組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2188941B (en) * 1986-04-14 1990-06-06 Bayer Ag Monoclonal antibodies recognizing human interleukin-2-receptor
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
HUT60768A (en) * 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules
EP0631783A1 (en) * 1993-06-03 1995-01-04 Mitsubishi Chemical Corporation Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives
US5567590A (en) * 1994-01-06 1996-10-22 National Jewish Center For Immunology And Respiratory Methods of diagnosing steroid-resistant inflammation due to type I or type II nuclear glucocorticoid receptor binding abnormalities
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
PT1100829E (pt) * 1998-07-27 2007-12-06 Univ London Utilização de moléculas de ligação à cd25 no tratamento de artrite reumatóide e doenças cutâneas
WO2000025816A1 (en) * 1998-10-30 2000-05-11 The University Of Miami Treatment of hepatitis c by administration of anti-il-2 receptor monoclonal antibody and an antiviral compound
GB0007911D0 (en) * 2000-03-30 2000-05-17 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
WO2002081508A2 (en) 2002-10-17
KR100975042B1 (ko) 2010-08-11
IL158060A (en) 2009-12-24
DE60228945D1 (de) 2008-10-30
HUP0400986A2 (hu) 2004-08-30
KR20080110687A (ko) 2008-12-18
NO20034453L (no) 2003-12-04
US20040146508A1 (en) 2004-07-29
US20090274691A1 (en) 2009-11-05
NZ528411A (en) 2005-04-29
NO20034453D0 (no) 2003-10-03
JP2005502593A (ja) 2005-01-27
CA2443405A1 (en) 2002-10-17
JP2009102367A (ja) 2009-05-14
MXPA03009115A (es) 2004-11-22
SK12212003A3 (sk) 2004-05-04
CN1527840A (zh) 2004-09-08
IL158060A0 (en) 2004-03-28
CN1296386C (zh) 2007-01-24
AU2002315271B2 (en) 2006-08-03
BR0208656A (pt) 2004-08-10
ATE408629T1 (de) 2008-10-15
PL363029A1 (en) 2004-11-15
ES2314067T3 (es) 2009-03-16
EP2058332A1 (en) 2009-05-13
HUP0400986A3 (en) 2012-09-28
PT1379557E (pt) 2008-12-29
WO2002081508A3 (en) 2003-08-28
EP1379557B1 (en) 2008-09-17
EP1379557A2 (en) 2004-01-14
KR20030088485A (ko) 2003-11-19

Similar Documents

Publication Publication Date Title
JP5604311B2 (ja) 疾患治療剤
MX2008011785A (es) Metodos de tratamiento de lupus utilizando anticuerpos cd4.
JP2021130668A (ja) 多発性骨髄腫（ｍｍ）の処置
AU2017234010B2 (en) Methods of treating or preventing graft versus host disease
US20090274691A1 (en) Use of CD25 binding molecules in steroid-resistant patients
US20240109977A1 (en) Anti-cd38 antibodies and their uses
AU2002315271A1 (en) Use of CD25 binding molecules in steroid-resistant patients
US20240132618A1 (en) Anti-cd38 antibodies for use in the treatment of antibody-mediated transplant rejection
JP2005502593A5 (https=)
RU2318537C2 (ru) Применение cd25-связывающих молекул для лечения пациентов, устойчивых к стероидам
WO2016102530A1 (en) Cyclic phosphoric acid derivative for the treatment of chronic fatigue syndrome
ZA200307401B (en) Use of CD25 binding molecules in steroid-resistant patients.
CN101015693A (zh) Cd25结合分子在类固醇耐受型患者中的用途
JP2022546686A (ja) 形質細胞に対する抑制剤または細胞傷害剤を使用する慢性疲労症候群の処置のための方法
AU2006235848A1 (en) Use of CD25 binding molecules in steroid-resistant patients
HK40115916A (zh) 施用嵌合抗原受体免疫疗法的方法
Nelson et al. Monoclonal Antibodies, T-Cell Receptors, and T-Cell Vaccines